LONDON, July 17, 2017 - Mapi, the developer of Linguistic Validation and provider of Clinical Outcome Assessments collaborates with YPrime, the clinical research technology provider, to streamline the deployment of validated assessments migrated onto YPrime's eCOA platform.
Mapi Language services and YPrime are leveraging cloud level integrations between technology platforms to establish an operational interface between Mapi's ISO 17100 certified process and YPrime's eCOA platform facilitating Linguistic Validations and direct screenshot reviews.
The collaboration will also bring integration for Mapi to directly develop and validate eCOAs on YPrime's platform eliminating the manual versioning and migrated questionnaire processes for new “born on eCOA” questionnaires. The cloud facilitated integration process helps with migration integrity of paper originated COAs.
"Working with MAPI is part of YPrime's strategy to simplify access and expedite start-up timelines to eCOA implementation for research organizations across the industry," said Mark Maietta, Chief Commercial Officer of YPrime. "We are thrilled about the opportunity to align our advanced platform with the largest provider of Patient-Centered Outcome instruments in this initiative. With established benefits in user experience, data quality and regulatory acceptance of eCOA solutions, I am confident this alliance will accelerate the already-burgeoning eCOA market adoption."
The new process will reduce the Linguistic Validation cycle and accelerate deployment enabling quicker “first patient in” timelines. Additionally, the alliance enables real time collaboration reducing review and correction cycles. The entire process tightly follows Mapi's ISO 17100 Certification and offers multi-language simultaneous development of validated eCOAs on YPrime's eCOA platform.
Press contact: Media@mapigroup.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.